Anavex life sciences announces presentation at 9th international conference on alzheimer's disease and related disorders in the middle east

New york, april 21, 2025 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company focused on developing innovative treatments for alzheimer's disease, parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including rett syndrome, and other central nervous system (cns) disorders, today announced that marwan noel sabbagh, md, professor of neurology at barrow neurological institute and chairman of anavex's scientific advisory board gave an oral presentation titled, “oral blarcamesine novel mechanism for alzheimer disease: autophagy restoration through upstream sigmar1 activation clinical efficacy phase iib/iii trial” at the 9th international conference on alzheimer's disease and related disorders in the middle east.
AVXL Ratings Summary
AVXL Quant Ranking